A Phase 3 interventional study of Tegaserod in Constipation, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-01.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Tegaserod is an aminoguanidine indole compound and a member of a new class of 5-hydroxytryptamine (5-HT) agonists. Activation of 5-HT4 receptors triggers the release of neurotransmitters from the enteric nerves which in turn stimulate contractility and peristalsis. This study will investigate the efficacy and safety of tegaserod against chronic constipation in a Chinese population of adult men and women
1,018 studies on the registry are indexed under Constipation; 139 are open to participants now.
This study's enrollment of 600 is above the median of 80 across 850 interventional studies indexed under Constipation.
Browse Constipation studies →Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other inclusion/exclusion criteria may apply.
Change from baseline in number of complete spontaneous bowel movements (CSBM) per week
Response rate for CSBM during the first 4 weeks of treatment
Patients' daily assessment of bowel habits
Patients' weekly assessment of constipation symptoms
Satisfactory relief of CC symptoms
PAC-QoL questionnaire
PPSM questionnaire
Safety
This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis